aTyr Pharma Secures FDA-Aligned Phase 3 Path for Efzofitimod in Pulmonary Sarcoidosis

What happened

aTyr Pharma announced it will advance efzofitimod into a Phase 3 study in pulmonary sarcoidosis after a Type C meeting with the FDA, using FVC as the primary endpoint and KSQ-Lung as a key secondary. This marks a critical turning point from the failed EFZO-FIT trial, as the FDA appears to have accepted a focused confirmatory path rather than requiring a large de novo study. The company plans to submit an IND in June 2026, signaling regulatory alignment and a defined timeline. Combined with the upcoming Nasdaq compliance deadline, this reduces the risk of forced dilutive actions and provides a clearer catalyst for value realization. Despite the positive step, the stock still trades near cash value, reflecting execution and financing uncertainties ahead.

Implication

Investors should monitor the IND submission in June and the Nasdaq compliance timeline. The FDA's endorsement of an FVC-driven study improves the probability of a successful regulatory outcome, but capital needs and litigation overhang still limit upside until further data. A position can be considered on pullbacks, given the reduced binary risk, but sizing should account for potential near-term volatility around financing and listing issues.

Thesis delta

The FDA's acceptance of a confirmatory study with FVC and KSQ-Lung endpoints recasts the risk/reward, as the bear case of a full EFZO-FIT redo is off the table. The probability of a bounded, financeable regulatory path has increased meaningfully, shifting the thesis from salvage to execution. The next key catalysts are the IND submission and Nasdaq compliance.